Astragalus for Anti-Inflammatory

Research suggests that Astragalus and its key bioactive components — polysaccharides, saponins, and flavonoids — demonstrate meaningful anti-inflammatory activity across a range of preclinical settings, with studies indicating these compounds can suppress pro-inflammatory cytokines such as TNF-α, IL-6, and MCP-1, inhibit the NF-κB and MAPK signaling pathways, shift macrophage polarization toward an anti-inflammatory state, and modulate interferon-driven inflammation in models of conditions such as psoriasis and diabetes-related vascular injury. The available evidence consists predominantly of in vitro cell studies, animal models, and narrative or comprehensive reviews of traditional Chinese medicine research, with several reviews specifically cataloging anti-inflammatory mechanisms for individual compounds including Astragaloside IV, astragalosides broadly, Astragalus polysaccharides, and formononetin. The overall direction of the assembled studies is supportive, with multiple independent lines of research converging on anti-inflammatory effects across different compound classes and disease contexts, and available reviews report a generally favorable safety profile. However, a significant limitation of this body of evidence is that the findings are largely preclinical, meaning the effects have been demonstrated primarily in laboratory and animal settings rather than in rigorous human clinical trials, so the extent to which these mechanisms translate to meaningful anti-inflammatory outcomes in people remains an open question.